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Significance of the Number of Positive Lymph Nodes in
Resected Non-small Cell Lung Cancer
Takayuki Fukui, MD,*† Shoichi Mori, MD,* Kohei Yokoi, MD,† and Tetsuya Mitsudomi, MD*
Background: In the current tumor, node, metastasis (TNM) classi-
fication of lung cancer, N status is defined by the anatomic extent of
lymph node metastases. In this study, we evaluated the prognostic
significance of the number of positive lymph nodes in resected
non-small cell lung cancer.
Methods: We retrospectively studied 289 patients with non-small
cell lung cancer who underwent surgery, and we compared the
prognostic significance of the number of positive nodes with the pN
number by using multivariate analysis. Patients were classified into
four groups according to the number of positive nodes: those
without nodal metastasis were n0, those with one to three positive
nodes were n1–3, those with four to six were n4–6, and those with
more than seven were n7.
Results: The 5-year survival rate was 77% in the n0 patients, 58%
in n1–3, 42% in n4–6, and 6% in n7, which indicates that an
increased number of positive lymph nodes was associated with poor
prognosis. Among the pN2 patients, the n1–3 group had a better
survival rate than the n4–6 and n7 groups. Multivariate analysis
showed that the number of positive nodes was a significant prog-
nostic factor, equal to the currently used pN number. Hazard ratios
for pN1 and pN2 with respect to pN0 were 2.13 and 3.49; and 2.07,
3.03, and 10.4 for n1–3, n4–6, and n7 with respect to n0. In addition,
we found that our classification could reflect the better prognoses of
skip or single-station nodal metastases.
Conclusion: The number of positive lymph nodes is a strong
independent prognostic factor in non-small cell lung cancer and may
add new information to the pN categories of the current TNM
classification.
Key Words: TNM classification, Skip metastasis, Single-station
metastasis.
(J Thorac Oncol. 2006;1: 120–125)
The presence and anatomic extent of histologically con-firmed lymph node metastases are important prognostic
factors for many malignancies. These factors, expressed in
terms of the N categories, are essential components of the
widely used tumor, node, metastasis (TNM) stage classifica-
tion.1 In the classification of lung cancer, only the anatomic
extent of lymph node metastasis defines the pathological N
(pN) categories, in which ipsilateral peribronchial and/or
hilar lymph node metastasis are defined as pN1; ipsilateral
mediastinal and/or subcarinal metastasis as pN2; and con-
tralateral mediastinal, contralateral hilar, or supraclavicular
metastasis as pN3. However, in the latest TNM classifica-
tions,2 the number of positive lymph nodes is included in the
definition of the pN categories in breast, gastric, and colo-
rectal cancer, and the pN status shows significant correlation
with patient prognosis.3–7
In non-small cell lung cancer (NSCLC), the number of
nodal stations with metastases has been suggested to be of
significance; however, few studies on the numbers of positive
lymph nodes have been reported.8,9 In this retrospective
study, we analyzed the clinicopathological data of 289 pa-
tients with NSCLC treated in a single institution, the Aichi
Cancer Center Hospital, to evaluate the prognostic signifi-
cance of the number of positive lymph nodes in surgically
resected NSCLC.
In addition, recent studies have suggested that patients
with “skip lymph node metastasis,” consisting of N2 disease
without N1 involvement (negative N1 and positive N2), tend
to have a better prognosis than other pN2 patients (positive
N1 and positive N2).10–19 Furthermore, the total number of
nodal stations with metastases seems to be an independent
prognostic indicator in patients with pN1 or pN2 NSCLC.8,20
We therefore analyzed whether the number of positive lymph
nodes could better reflect the prognosis in pN2 patients with
skip lymph node metastasis or single node-station metastasis.
PATIENTS AND METHODS
Patient Cohort
During the 5-year period between 1992 and 1996, 289
patients with primary NSCLC were enrolled in this study.
The patients with clinical stage IA to IIIA, including cN2
patients with single-station nodal metastasis, underwent sur-
gery. Fifty-three patients with clinical stage IIIA were in-
cluded in the cohort. All patients underwent pulmonary
resection with systematic nodal dissection of the hilum and
mediastinum at the Aichi Cancer Center Hospital. The pa-
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tients with bulky N2 disease with extranodal invasion were
excluded. In this study, we regarded bulky N2 with extran-
odal invasion as big lymph nodes that involved adjacent
structures including large vessels, trachea, bronchus, and
pleura with unclear boundaries. Neither induction therapy nor
adjuvant therapy was given to this series of patients. Patient
characteristics are shown in Table 1. The patients comprised
193 (67%) men and 96 (33%) women, ranging in age from 24
to 81 years (median  standard deviation, 61  9.7 years).
There were 178 (62%) adenocarcinomas, 83 (29%) squamous
cell carcinomas, and 28 (9%) other types of cancer. The
surgical procedures performed were lobectomy in 230 pa-
tients, bilobectomy in 23, pneumonectomy in 33, and seg-
mentectomy in three.
Analysis of Lymph Node Metastasis
Lymph nodes were dissected from the adipose connec-
tive tissue of the corresponding anatomic regions, as subdi-
vided by the surgeon immediately after the operation. The
lymph nodes classified in this way were sent for histopatho-
logical examination after hematoxylin and eosin staining. The
numbers of positive lymph nodes from each defined anatomic
region were recorded. Based on the data obtained, stratifica-
tions were performed according to two different modes of
lymph node status assessment: the absence or presence and
anatomic extent of nodal metastases (pN categories) as de-
fined by the TNM classification according to the lymph node
mapping; and the number of regional lymph nodes with
metastases—the number categories—in which stratification
was performed based only on the numbers of positive nodes,
ignoring the anatomic extent of the regional lymph node
involvement.
Because each T or N status is classified into four
subgroups in the current TNM classification, we decided to
make four categories. Because all the patients with seven or
more positive lymph nodes were included pN2 category, we
defined the patients as one group (Figure 1). The patients with
one to six positive lymph nodes were just divided into two
groups in the middle of the number. Thus, the absence of
nodal metastasis was defined as n0 (that is, identical to pN0);
the presence of one to three positive lymph nodes was defined
as n1–3; four to six nodes was defined as n4–6, and seven or
more nodes was defined as n7.
Statistical Analyses
The Kaplan–Meier method was used to plot the sur-
vival curves, and the log-rank test was used to evaluate
differences among the subgroups. Student’s t test was used to
compare the numbers of lymph nodes with metastases among
each group. To evaluate the significance of the number
category as an independent prognostic factor, we performed
multivariate analysis by using Cox’s proportional hazards
model with two different models: one that included pN status
and one that included the number category. Trend P was
assessed by score tests. All patients in this study were
followed for at least 5 years or until death. P values 0.05
were regarded as statistically significant. Statistical calcula-
tions were performed using a statistical package (StatView
version 5.0; SAS Institute Inc., Cary, NC).
TABLE 1. Patient characteristics
No. (%)
Age
 61 years 131 (45)
 61 years 158 (55)
Gender
Male 193 (67)
Female 96 (33)
Smoking history
 20 pack-years 117 (40)
 20 pack-years 172 (60)
Histology
Adenocarcinoma 178 (62)
Squamous cell carcinoma 83 (29)
Other 28 (9)
pT status
pT1 131 (45)
pT2 125 (43)
pT3 28 (10)
pT4 5 (2)
pN status
pN0 190 (66)
pN1 35 (12)
pN2 64 (22)
Pathological stage
IA 99 (34)
IB 72 (25)
IIA 12 (4)
IIB 37 (13)
IIIA 63 (22)
IIIB 6 (2)
Number of positive LNs
0 190 (66)
1–3 63 (22)
4–6 19 (7)
 7 17 (5)
LN, lymph nodes.
FIGURE 1. Distribution of the number of positive lymph
nodes in 99 pN() patients. The pN1 and pN2 patients are
shown in gray and black, respectively.
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RESULTS
The mean ( SD) nodal yield was 22  8.8 per patient
(range, 3–59). At least one nodal metastasis was found in 99
(34%) patients. The distribution of the number of lymph node
metastases in 99 pN() patients is shown in Figure 1. The
breakdown by number category was 190 n0 patients, 63 n1–3
patients, 19 n4–6 patients, and 17 n7 patients. No significant
difference in clinical factors such as age, gender, smoking
history, tumor histology, and performed surgical procedure,
was observed among the defined subgroups. The mean num-
ber of positive lymph nodes in those patients with at least one
lymph node metastasis was 3.9  4.2 (range, 1–28). The
mean number of positive lymph nodes was 1.9  1.3 (range,
1–6) in patients classified as pN1 and 5.0 4.7 (range, 1–28)
in patients classified as pN2, with a significant difference
between each of the pN categories (P  0.0001) (Table 2).
Thus, the number of positive lymph nodes correlated with the
anatomic extent of the metastasis.
The 5-year survival rate of the 190 patients without
nodal metastasis (pN0) was 77% in this study, which was
significantly better than that of patients classified as pN1
(57%) and pN2 (40%) (P  0.0001) (Figure 2). With respect
to the number category, the 5-year survival rate was 77% for
n0, 58% for n1–3, 42% for n4–6, and 6% for n7, which
indicates that an increased number of lymph nodes with
metastases is associated with poor prognosis (P  0.0001)
(Figure 3). Similar differences in survival were observed
among pN2 patients who were divided into subgroups n1–3
(32 patients), n4–6 (15 patients), and n7 (17 patients) (P 
0.0001), but not between subgroups n1–3 (31 patients) and
n4–6 (four patients) among pN1 patients (Figure 4). In addi-
tion, similar differences were observed in the patients divided
into subgroups by pathological type, such as adenocarcinoma
and squamous cell carcinoma (data not shown).
Hazard ratios for pN1 and pN2 versus pN0 were 2.13
and 3.49, respectively; and 2.07, 3.03, and 10.4 for n1–3, n4–6,
and n7, respectively, versus n0 by multivariate analysis
using Cox’s proportional hazards model (Tables 3 and 4).
Among the clinicopathological variables analyzed, the num-
ber category, determined by the number of positive lymph
nodes after lymphadenectomy, was an independent prognos-
tic factor similar to the pathological N category defined by the
anatomic extent of lymph node metastases
In the current study cohort, the patients with skip
metastasis had a significantly better prognosis, with 5-year
survival rates of 55% compared with 31% for the other pN2
patients (P  0.04) (Table 5). Comparing the patients with
skip metastasis versus those without skip metastasis in 64
pN2 patients, the numbers of positive lymph nodes were
2.0  1.6 and 6.9  5.1, respectively (P  0.0001). Simi-
larly, among the pN2 group, patients with single N2 lymph
node metastasis, including single N2 station metastasis, had a
significantly better prognosis than those with multiple lymph
node metastases (P  0.007, data not shown).
DISCUSSION
The stage grouping of the TNM subsets was developed
to provide high specificity for identifying patient groups with
similar prognoses and treatment options. Because the extent
of lymphatic spread is considered to reflect the aggressive-
ness of cancer cells and because extensive nodal metastasis
implies poor survival, lymph node status assessment contin-
ues to be an essential component of the stage classification for
many kinds of cancer. In the latest TNM classification, as
revised in 1997, the anatomic extent of lymph node metas-
TABLE 2. Number of Positive Lymph Nodes and pN Status
Number of positive lymph nodes
Mean number  SD0 1–3 4–6 >7
pN1 – 31 4 0 1.9  1.3
pN2 – 32 15 17 5.0  4.7
P  0.0001
FIGURE 2. Survival curves for subgroups stratified accord-
ing to pN status. The 5-year survival rate and the number of
patients at risk in each subgroup are indicated. The survival
curves showed significant stepwise deterioration as the pN
number increased.
FIGURE 3. Survival curves according to the number of pos-
itive lymph nodes. The 5-year survival rate and the number
of patients at risk in each subgroup are indicated. The sur-
vival curves showed significant stepwise deterioration as the
number increased. The feasibility of the application of our
classification was confirmed.
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tasis defines pN categories in lung cancer. In contrast, the
number of positive lymph nodes is included in the definition
of pN categories in breast, gastric, and colorectal cancers.
To evaluate the prognostic significance of the number
of positive lymph nodes in primary NSCLC, we defined the
“number” category for 289 patients in NSCLC. The survival
curves in accordance with the number categories showed
significant stepwise deterioration as the number increased,
and the feasibility of applying our classification was con-
firmed. Multivariate analysis using Cox’s proportional haz-
ards model revealed that the number categories might be
considered as indicators of prognosis similar to the current
TNM classification based on the anatomic extent of nodal
metastases. These results suggest that the number of positive
lymph nodes is a strong independent prognostic factor in
NSCLC. Specifically, remarkable results of the similar sur-
vival rate between pN1 and pN2 limited in n1–3 patients and
the better survival rate in n1–3 patients among pN2 versus
n4–6 among pN1 patients were observed. These results
seemed to be a real challenge for current pN category of
NSCLC. Consequently, the number category should be useful
in determining patients who should receive adjuvant therapy.
Meanwhile, similar differences in survival among the sub-
groups, n0, n1, n2–4, and n5, which divided n1–3 patients into
two categories, were observed. Therefore, further discussion
about the pattern of division of positive nodes will be neces-
sary when the system undergoes revision.
A similar stepwise deterioration of survival as the
number increased was also observed in 64 patients in the pN2
group. Patients with N2 NSCLC are a heterogeneous sub-
TABLE 3. Multivariate Analysis by Cox’s Proportional
Hazards Model Including pN Status
Variable
Hazard
ratio 95% CI P value
Age (61 vs. 61 years) 1.73 1.15–2.60 0.009
Gender (male vs. female) 1.29 0.68–2.46 0.441
Smoking (20 vs. 20 pack-years) 1.04 0.56–1.91 0.909
Histology (non-sq vs. sq) 1.02 0.65–1.61 0.925
Tumor size (3 vs. 3 cm) 1.87 1.22–2.88 0.004
pN status
pN1/pN0 2.13 1.20–3.77 0.010
pN2/pN0 3.49 2.28–5.36 0.0001
Trend P for pN  0.0001
Sq, squamous cell carcinoma.
TABLE 4. Multivariate Analysis by Cox’s Proportional
Hazard’s Model Including the Number of Positive Lymph
Nodes
Variable
Hazard
ratio 95% CI P value
Age (61 vs. 61 years) 1.63 1.07–2.50 0.024
Gender (male vs. female) 1.50 0.78–2.91 0.226
Smoking (20 vs. 20
pack-years)
0.89 0.48–1.67 0.719
Histology (non-sq vs. sq) 0.84 0.53–1.34 0.462
Tumor size (3 vs. 3 cm) 1.83 1.19–2.81 0.006
The number of positive LNs
1–3/0 2.07 1.29–3.31 0.003
4–6 / 0 3.03 1.57–5.85 0.001
 7/0 10.4 5.71–19.0 0.0001
Trend P for the number category 0.0001
LN, lymph node; sq, squamous cell carcinoma.
TABLE 5. Summary of Skip and Nonskip Groups of pN2
Patients
Pattern of LN metastasis
Skip Nonskip P value
Patients 25 39
LNs (mean  SD) 2.0  1.6 6.9  5.1 0.0001
5-year survival rate 55.4% 30.8% 0.04
Skip, N1(-) and N2(); Nonskip, N1() and N2(); LNs, lymph nodes.
FIGURE 4. Survival curves according to the number cate-
gories among pN1 and pN2 patients. The 5-year survival
rate and the number of patients at risk in each subgroup are
indicated. Significant differences in survival were observed
among pN2 patients who were divided into subgroups n1–3,
n4–6, and n7 (P  0.0001) (B), but not between subgroups
n1–3 and n4–6 for pN1 patients (A).
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group in regard to their prognosis and treatment. Some
authors have proposed new TNM classifications to classify
N2 disease into subcategories. For example, homogeneous
N2 NSCLC prognostic subgroups determined by combined
pretreatment and postoperative staging consisting of diagnos-
tic imaging results, and the lymph node levels involved were
suggested as a guide to preoperative staging and to the
selection of appropriate treatment options.10 The number
category used in our analysis could also divide the N2
patients into homogeneous subgroups.
Recent studies have suggested that patients with skip
lymph node metastases tend to have a better prognosis than
other pN2 patients 11–19 and that the total number of stations
with metastases is an independent prognostic indicator in
patients with completely resected pathological N1 or N2
NSCLC.8,20 Thus, the group of pN2 patients with NSCLC is
also considered heterogeneous on survival, according to the
presence of skip or single-station metastasis. The better
prognosis of patients with skip metastasis may be attributed
to the smaller number of positive lymph node or to subpleural
lymphatic channels that can drain directly to the mediasti-
num. Both possibilities exist. It is very difficult to conclu-
sively determine the mechanism from our current knowledge.
Our analyses suggest that number category could reflect the
better prognosis of skip or single-station lymph node metas-
tasis in pN2 patients and may have the potential for stratifi-
cation of patients with lymph node metastases to single or
multiple N2 stations.
Despite these benefits of the number category, our
category system cannot help to define treatment options for
primary lung cancer because preoperative clinical staging
consists of imaging studies. To date, neither computed to-
mography nor positron emission tomography could success-
fully detect each positive lymph node during preoperative
evaluation. However, it may be possible to use the number
category for preoperative evaluation if a new device that can
identify each lymph node and qualitative diagnosis is devel-
oped in the future.
Meanwhile, the extent of lymphadenectomy and the
thoroughness of lymph node retrieval decide the total number
of resected lymph nodes for each specimen, and the signifi-
cance of the number categories varies among countries and
institutions. In gastric cancer, a higher probability of detect-
ing nodal metastases with increasing nodal yields has been
confirmed and follows an exponential model, with extended
lymphadenectomy leading to an increase in the number of
nodes with metastases.21 In addition, the number of positive
lymph nodes is considered to reflect only the anatomic extent
of the lymph node metastases. In fact, the numbers of positive
lymph nodes correlated significantly with the pN categories
based on the current TNM classification, with stepwise dete-
rioration of survival as the pN number increased (Table 2)
(Figure 2).
The adequacy of mediastinal lymph node sampling or
the reduction of the extent of lymph node dissection in lung
cancer has been discussed.22,23 Although this trend leads to
fewer lymph nodes being harvested, the priority of our
number category will be stable as far as less dissection is
based on the concept of sentinel lymph node.
Although the number category contains some deficien-
cies, such as difficulty in determining nodal status based on
imaging studies in preoperative evaluation, from the strong
correlation between the number and pN categories, we con-
clude that the number category is a strong independent
prognostic factor in NSCLC and can add new information to
pN status in breast, gastric, and colorectal cancers. Further-
more, the number category may allow stratification of N2
patients into homogeneous subgroups. These findings should
be confirmed by others, and consideration should be given to
its inclusion in future pathological staging of NSCLC when
the system undergoes revision.
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